Research programme: Hedgehog cell-signalling pathway stimulants - MAX BioPharma

Drug Profile

Research programme: Hedgehog cell-signalling pathway stimulants - MAX BioPharma

Alternative Names: Hedgehog signalling pathway activators - MAX BioPharma; Oxy 200; Oxy-133; Small molecule oxysterols - MAX BioPharma

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MAX BioPharma
  • Class Small molecules; Sterols
  • Mechanism of Action Hedgehog cell signalling pathway stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Osteoporosis

Highest Development Phases

  • Preclinical Non-union fracture; Osteoporosis

Most Recent Events

  • 12 Jul 2017 Research programme: Hedgehog cell-signalling pathway stimulants - MAX BioPharma is available for licensing as of 10 Jul 2017. www.maxbiopharma.com
  • 10 Jul 2017 Preclinical trials in Osteoporosis in USA (PO) before July 2017
  • 10 Jul 2017 Pharmacodynamics data of oxy 200 from a preclinical study in Osteoporosis released by MAX BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top